Last updated Jun 7, 2026
Lilly
Evidence Sources
7
Competitive Findings
0
Portfolio Developments
3
Regulatory Precedents
7
Clinical Programs
1
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 3
- Self-competition findings removed: 3
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- Antibiotic
- Pain Management
- Anesthesia
- Musculoskeletal
Highest priority development: Emerging Anesthetic Techniques and Opioid
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 72%
Active Signals
3
Investigate Priority
0
Opportunity Score
69
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 7, 2026Score 27FDA Grants AP Status for Doxycycline Hyclate Supplement by Impax Labs
Infectious Disease · Antibiotic
- MonitorJun 2, 2026Score 23Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction
Pain Management · Anesthesia
- MonitorJun 2, 2026Score 19Pilot Study on Geniculate Artery Embolization for Knee Osteoarthritis Initiated
Musculoskeletal · Osteoarthritis
Related Assets
Portfolio asset pages with evidence-based assessments.
- Emerging Anesthetic Techniques and OpioidModerate Confidence · 78%
Portfolio asset at Phase II stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)LillyFDAPortfolio
- Low Confidence · 0%Sources (3)LillyClinicalTrials.govPortfolio
- Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 TrialLow Confidence · 0%
Phase II success
Sources (3)LillyClinicalTrials.govPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — DOXYCYCLINE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — COLESTIPOL HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TETRACYCLINE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — METHYLPHENIDATE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Emerging Anesthetic Techniques and OpioidModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Lilly right now?
- Which regulatory precedents should Lilly monitor in Infectious Disease and Antibiotic?
- How does Emerging Anesthetic Techniques and Opioid compare to the nearest competitive programs?
- What signals require immediate investigation for Lilly?
- Summarize the strategic implications of recent developments for Lilly.
- Where is the greatest uncertainty in Lilly's competitive positioning?